Funding
The MRI-GENIE study was funded by NIH NINDS (R01NS086905, NSR PI). M.B was supported by the ISITE-ULNE Fundation, the Société Française de Neuroradiologie, the Société Française de Radiologie, the Thérèse and René Planiol Fundation. A.K.B. is supported by a MGH ECOR Fund for Medical Discovery (FMD) Clinical Research Fellowship Award. MRE is supported by the American Academy of Neurology and MGH Executive Council on Research. PMR is supported by NIH K01 HL128791. TT was supported by the Helsinki University Central Hospital, Sigrid Juselius Foundation, Sahlgrenska University Hospital, and University of Gothenburg. A.G.L was supported by the Swedish Research Council (2019-01757), CaNVAS project funded by NIH (US) The Swedish Government (under the Avtal om Läkarutbildning och Medicinsk Forskning, ALF), The Swedish Heart and Lung Foundation, Region Skåne, Lund University, Skåne University Hospital, Sparbanksstiftelsen Färs och Frosta, Fremasons Lodge of Instruction Eos in Lund. C.J. was supported by the Swedish Research Council (2018-02543); the Swedish Heart and Lung Foundation (20190203); and the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (ALFGBG-720081) PL is supported by NIH NIBIB NAC P41EB015902; The funders had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Contributions
Conception and design of the study: MB, AKB, MDS, SH, MRE, RM, CW, RWR, XL, RL, GK, NSR; Acquisition and analysis of data: MB, AKB, MDS, SH, DAV, KD, AKG, MRE, MN, ORB, JWC, AD, CJG, LH, LH, JKJ, JJC, SJK, RL, CRL, PFM, CWM, JFM, CLP, AR, SR, JR, JR, TJ, RLS, RS, PS, AS AS, TMS, DS, TT, VT, AV, JWC, DW, OW, RZ, BBW, JM, AL, CJ, PG, GK, NSR; Drafting a significant portion of the manuscript or figures: MB, AKB, SH, MDS, MRE, RWR, XL, RL, GK, NSR
Competing interests
M.E. has received personal fees for consulting from Astra Zeneca and WorldCare Clinical Group. C.G. has received consulting honoraria from Microvention and Stryker and research funding from Medtronic and Penumbra. A.V. has received research funding from Cerenovus. A.G.L. has received personal fees from Bayer, Astra Zeneca, BMS Pfizer, and Portola. N.S.R. has received compensation as scientific advisory consultant from Omniox, Sanofi Genzyme and AbbVie Inc.